Types segmentation of the Monoamine Oxidase Inhibitors (MAOIs) Medications market categorizes products into non‑selective MAOIs, selective MAO‑A inhibitors, and selective MAO‑B inhibitors. Non‑selective agents, exemplified by phenelzine and tranylcypromine, still command approximately 40 % of market value despite safety concerns, because they retain efficacy across both depressive and anxiety spectrums. Selective MAO‑A inhibitors such as moclobemide account for roughly 25 % of sales; their reversible binding profile reduces dietary restrictions, expanding adoption in outpatient psychiatric care. Selective MAO‑B inhibitors, including selegiline and rasagiline, dominate the remaining 35 % and are primarily linked to the Parkinson’s disease application segment, where neuro‑protective benefits justify premium pricing. The relative weight of each type mirrors clinical guideline preferences, patent expiry timelines, and the intensity of generic competition. Consequently, the market taxonomy reveals that strategic focus on selective MAO‑B agents can drive higher margin growth, while non‑selective products rely on niche positioning and price‑sensitivity management. In addition, emerging combination therapies that pair MAO‑B inhibitors with levodopa are projected to expand the addressable patient pool, further reinforcing the premium status of this subtype.
